Floatz logo

Autologous Dendritic Cell-Tumor Cell Immunotherapy

Metastatic Melanoma

Lisata Therapeutics, Inc.Cell therapyPhase 3Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
73/ 100

Competitive context

87 Active assets in the Metastatic Melanoma cohort.

Asset / SponsorPhaseRating
DACARBAZINE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
TIL
East Metropolitan Health Service, Australia
Phase 2BB
Ipilimumab
NYU Langone Health
Phase 4BB
Irinotecan
Melanoma and Skin Cancer Trials Limited
Phase 2BB

View all 50 →

Same molecule, other indications

Autologous Dendritic Cell-Tumor Cell Immunotherapy is also rated in:

metastatic melanomaDormant
CC
Indicative ·
47 / 100
View asset →
melanomaDormant
CC
Indicative ·
47 / 100
View asset →
Glioma, MalignantDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →